<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818931</url>
  </required_header>
  <id_info>
    <org_study_id>2018-4107</org_study_id>
    <nct_id>NCT04818931</nct_id>
  </id_info>
  <brief_title>Does a Preoperative Prophylactic Antibiotic Reduce Surgical Site Infection Following Wire-localized Lumpectomy</brief_title>
  <official_title>Does a Preoperative Prophylactic Antibiotic Reduce Surgical Site Infection Following Wire-localized Lumpectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Data on the benefits of preoperative prophylactic antibiotics for breast surgery&#xD;
      are conflicting and there is no guideline for their use for wire-localized lumpectomy. The&#xD;
      aims of this study were to determine whether a single dose of pre-operative antibiotic&#xD;
      reduces surgical site infection (SSI) for wire-localized lumpectomy and to identify risk&#xD;
      factors for SSI.&#xD;
&#xD;
      Methods: This was a prospective randomized trial carried out from April 2018 to June 2019 at&#xD;
      the &quot;Centre des Maladies du Sein du CHU de Québec - Université Laval&quot;, a tertiary center&#xD;
      specialized in breast surgery. After informed consent, patients who underwent wire-localized&#xD;
      lumpectomy were randomized to receive or not a pre-operative single dose of prophylactic&#xD;
      antibiotic (cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy). Data&#xD;
      regarding demographics, comorbidities, perioperative details, and SSI were analyzed. SSI was&#xD;
      considered if: 1) patient had positive wound cultures; or 2) required abscess drainage; or 3)&#xD;
      received antibiotic treatment for breast symptoms (e.g., swelling, erythema, congestion)&#xD;
      within 30 days after operation, in the absence of wound culture or in the presence of&#xD;
      negative results. The patients and the investigator responsible for data collection were&#xD;
      blind to grouping. All patients were called 30 days after surgery to be sure that they did&#xD;
      not consult at another hospital for surgical wound infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2018</start_date>
  <completion_date type="Actual">December 10, 2019</completion_date>
  <primary_completion_date type="Actual">June 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with surgical site infection in each group</measure>
    <time_frame>within 30 days after operation</time_frame>
    <description>1) patient had positive wound cultures; or 2) required abscess drainage; or 3) received antibiotic treatment for breast symptoms (e.g., swelling, erythema, congestion)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antibiotics</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin Injection</intervention_name>
    <description>cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy</description>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years of age&#xD;
&#xD;
          -  female&#xD;
&#xD;
          -  scheduled for a wire-localized lumpectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  incapacity to give informed consent&#xD;
&#xD;
          -  preoperative breast infection&#xD;
&#xD;
          -  patients known to be colonized with MRSA&#xD;
&#xD;
          -  immunocompromised patients&#xD;
&#xD;
          -  preoperative antibiotic prophylaxis needed for any concomitant condition.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Québec - Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

